Preferentially expressed antigen in melanoma (PRAME) peptide (100-108) presented by Human leukocyte antigen A*02:01 (HLA-A*02:01) (PRAME100-108/HLA-A*02:01)

Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen (CTA) that acts as a repressor of retinoic acid receptor (RAR) signaling, thereby promoting tumor cell proliferation and inhibiting apoptosis [3]. The PRAME100-108 peptide, a nonamer with the sequence VLDGLDVLL, is a highly immunogenic epitope that is naturally processed and presented on the cell surface by the Human leukocyte antigen A*02:01 (HLA-A*02:01) molecule [4]. This specific peptide-MHC complex is a validated target for immunotherapy because PRAME is overexpressed in various cancers—including melanoma, uveal melanoma, and acute myeloid leukemia—while remaining largely absent in healthy adult tissues, except for the immune-privileged testis [3]. Current therapeutic approaches targeting this complex include TCR-engineered T-cell therapies (TCR-T), such as IMA203, and TCR-bispecific molecules like IMC-F106C, which redirect T cells to recognize and kill PRAME-presenting tumor cells [1, 2]. Clinical development of these agents requires patient screening for both the HLA-A*02:01 allele and sufficient PRAME expression levels to ensure efficacy and safety [1, 2].

Other names

PRAME VLDGLDVLL peptideHLA-A*02:01-restricted PRAME antigenPRAME-A2 complexVLDGLDVLL-HLA-A*02:01

T-cell receptor (TCR) mediated recognition and lysis of tumor cells; Bispecific T-cell engagement (ImmTAC)